← All trials
NCT05428202
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2022
- Primary completion
- Apr 28, 2022
- Completion date
- Aug 30, 2022
- First posted
- Jun 23, 2022
- Last posted
- Jul 27, 2022
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Erciyes UniversityLead sponsor
- Erciyes UniversityReponsible party - principal investigator
- MonitorCROCollaborator
- MonitorCROStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.